Abstract
Medarex and Bristol-Myers Squibb are developing ipilimumab, an immunostimulatory human antibody against cytotoxic T-lymphocyte antigen-4, for the potential combination or monotherapy treatment of melanoma, prostate, breast, renal and other cancers, as well as HIV infection.
MeSH terms
-
Antibodies / adverse effects
-
Antibodies / immunology
-
Antibodies / therapeutic use*
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal / biosynthesis
-
Antibodies, Monoclonal / pharmacokinetics
-
Antibodies, Monoclonal / therapeutic use*
-
Antigens, CD
-
Antigens, Differentiation / immunology
-
CTLA-4 Antigen
-
Clinical Trials as Topic
-
Drug Evaluation, Preclinical
-
Drug Industry*
-
Drug Therapy, Combination
-
Humans
-
Immunotherapy*
-
Ipilimumab
-
Neoplasms / drug therapy*
-
Neoplasms / immunology
-
Patents as Topic
Substances
-
Antibodies
-
Antibodies, Monoclonal
-
Antigens, CD
-
Antigens, Differentiation
-
CTLA-4 Antigen
-
CTLA4 protein, human
-
Ipilimumab